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Background: Contrast-induced nephropathy is a serious complication after percutaneous coronary intervention (PCI). Glycemic levels 
abnormalities (hyper/hypoglycemia) before PCI may amplify the pathogenetic mechanisms of this complication. Moreover the protective effects of 
insulin and N-Acetyl-Cysteine (NAC) on the kidney function have emerged. We sought to evaluate the efficacy of glucose-insulin-potassium (GIK), with 
or without administration of NAC, in prevention of contrast-induced nephropathy, by plasmatic measurements of Neutrophil Gelatinase-Associated 
Lipocalin (pNGAL), a new early marker of acute kidney injury.
Methods: We randomized diabetic and/or with chronic renal failure patients to 3 different protocols: ISS, ISS-GIK, ISS-GIK-NAC. ISS infusion was 
started 12 hours before PCI up to 24 hours after. GIK infusion was administered from 12 hours before up to 12 hours after. NAC was given as oral 
doses of 1200 mg 12 hours and 1 hour before PCI. Blood samples were collected before and after PCI to evaluate serum creatinine and pNGAL.
Results: We report the results on the first 48 patients. We observed a significant reduction of pNGAL levels after PCI in the overall population 
(basal pNGAL 145±41 vs 6 h pNGAL 138±49 ng/ml; p<0.001). In particular, in ISS-GIK-NAC group pNGAL decrease was of -18.6±20% (p=0.032 vs 
ISS), in ISS-GIK group of -5.9±23% (p=0.168 vs ISS), while a pNGAL increase of 14.9±51 % was observed in ISS group (p for trend=0.067). Serum 
creatinine variation was -5.3±13% in ISS-GIK-NAC group (p=0.039 vs ISS), -5.4±10% in ISS-GIK group (p=0.02 vs ISS) and 4.0±11% in ISS (p for 
trend=0.039). Similar results has been noticed for creatinine clearance.
Conclusions: GIK infusion has been of some efficacy in preventing the contrast-induced nephropathy in diabetic and with chronic renal 
impairment patients undergoing PCI. NAC administration, as anti-oxidant agent, has been associated with a further decrease of post-PCI pNGAL, 
suggesting the sensitivity of this protein to oxidative damage on tubular epithelial cells induced by the contrast medium. Moreover for the first time 
pNGAL has been used for the evaluation of the efficacy of a nephro-protection protocol.
